New Triple-Threat attack on tough bile duct cancer
NCT ID NCT06439485
Summary
This study is testing whether a combination of three drugs can help control advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic change called an FGFR2 fusion. The trial will enroll about 25 adults whose cancer has progressed after standard treatment. Researchers aim to find the safest dose and see if this triple combination can shrink tumors and slow the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.